# Roche

Source: https://onco.cc/companies/da-roche/  
OnCo record `da-roche` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Roche is developing trontinemab and has studied prasinezumab against alpha-synuclein.

## Summary

Map node for Brainshuttle amyloid and synuclein antibody programmes. Pipeline status is not a recommendation to use an unapproved medicine.

## Fields

- Kind: Company
- Last checked: 2026-09-21
- Tags: dementia-atlas
- HQ: Basel
- Type: pharma
- Website: https://www.roche.com/

## Sources

- Roche: https://www.roche.com/

## Connected records

- drugs: [Prasinezumab](https://onco.cc/drugs/da-prasinezumab/), [Trontinemab](https://onco.cc/drugs/da-trontinemab/)
- trials: [Prasinezumab (PASADENA / related)](https://onco.cc/trials/da-trial-prasinezumab/), [TRONTIER 2 (trontinemab Phase 3)](https://onco.cc/trials/da-trial-trontier/)
- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-roche.json